PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.15%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
-30.87%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.35%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-30.35%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-2.47%
Both companies reducing D&A. Martin Whitman would check industry patterns.
30.79%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.35%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-41.49%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
30.26%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
30.26%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.58%
EPS growth while CRVO declines. John Neff would investigate advantages.
33.88%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
0.94%
Share count reduction exceeding 1.5x CRVO's 2.84%. David Dodd would verify capital allocation.
5.92%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.